Skip to main content
. 2001 Jan;51(1):61–70. doi: 10.1046/j.1365-2125.2001.01301.x

Table 4.

Population pharmacokinetic model of thioTEPA.

Model: CL = θ1 + θ9*(AP-57) + θ10*(ALB-43); V1 = θ2 + θ11*(TP-61); k12 = θ3; k21 = θ4, fm*= θ5; k = θ6 + θ12*(WGT-68); k34 = θ7; k43 = θ8.

Parameter Population value (RSD)1 Interindividual variability (%) (RSD)1 Interoccasion variability (%) (RSD)1
θ1 CL (l*h–1) 34.0 (0.067) 18 (0.33) 11 (0.35)
θ2V1 (l) 46.9 (0.062)  7.5 (2.1) 19 (0.54)
θ3k12 (h–1)  0.304 (0.17)
θ4k21 (h–1)  0.408 (0.20) 51 (0.60)
θ5 fm* (l–1)  0.0295 (0.17) 39 (0.37) 32 (0.59)
θ6k (h–1)  0.636 (0.23) 27 (0.67) 32 (0.32)
θ7 k34 (h–1)  2.75 (0.23)
θ8 k43 (h–1)  0.851 (0.094) 25 (058)
θ9 CL Alkaline phosphatase −0.0727 (0.53)
θ10 CL Serum albumin  0.449 (0.49)
θ11V1 Total protein  0.751 (0.45)
θ12k Body weight  0.00736 (0.46)
Proportional error thioTEPA (%) 28.7
Additive error thioTEPA (µm)  0.0209
Proportional error TEPA (%) 22.4
1

RSD = relative standard error of estimate.